louisiana glp-1 bowel obstruction class action gastric intestinal legal team in gastrointestinal Glucagon-like Peptide-1 Receptor Agonists Associated Novo Nordisk is suing Eli

I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened by Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Summary Eli Lilly's GLP-1 portfolio outpaces Novo Nordisk's sluggish performance, supported by the former's superior tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth

[Google Scholar] Dickinson DA, Forman HJ

Food and Drug Administration (FDA) [9]

Khan M, Meduru S, Mostafa M, Khan S, Hideg K, Kuppusamy P